Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
about
The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranNon-vitamin-K oral anticoagulants and laboratory testing: now and in the future : Views from a workshop at the European Medicines Agency (EMA)Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary EvidenceNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentPharmacology of anticoagulants used in the treatment of venous thromboembolismNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewReal Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.Trends in the development of oral anticoagulants.Perioperative management of patients on direct oral anticoagulants.Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot TrialManaging target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Laboratory measurement of the anticoagulant activity of edoxaban: a systematic reviewSupporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offsEfficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.Anticoagulation in Atrial Fibrillation - Current ConceptsClinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillationEconomic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Using new oral anticoagulants in patients undergoing major orthopedic surgery.New oral anticoagulant and antiplatelet agents for neurosurgeons.Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.Laboratory measurement of the direct oral anticoagulants.Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.The laboratory's 2015 perspective on direct oral anticoagulant testing.When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation.Drug-drug interactions of non-vitamin K oral anticoagulants.Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.Direct oral anticoagulants: unique properties and practical approaches to management.Novel oral anticoagulant management issues for the stroke clinician.Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.
P2860
Q26776239-D33B4633-D55A-438D-9E7A-3339441C7B43Q26799710-50CFA184-483E-4813-B6BE-DE0DC7300CC0Q28067412-61A72355-B95B-4CA5-9424-C899698D2A95Q28071393-211DFB6E-1AD8-431C-817F-25D103E52499Q28071657-7AB952BC-DCDF-404D-8127-1F5CEFD8CF28Q28076077-28C5E80B-C370-41EA-977C-C1D28BA0A622Q28078967-EA612E38-D889-47D6-8942-2D9F1731B094Q28081918-0BD9DCD2-9321-4C25-9EDA-72B448AB4E3FQ31098679-23A018C2-F3F3-4621-97CA-A084F0956E80Q33424198-8DFEC511-123A-41E7-A3F5-2A758AC19404Q33692054-651F683E-9E72-480B-AEAD-CE8F316AA72CQ33698353-63090301-337C-4923-97AA-B2FE5FC6B541Q34667503-69DB6AEB-BF92-4E85-9A8B-AE61B1CE40A8Q34670808-30039DBE-04DC-4DD1-8B21-BFFA2D78FCE8Q35559027-8C819C87-55E6-4473-8EE7-0FFAEBFF5F99Q35923721-1B32C489-C42B-4FFE-BCA7-0DB8DA59B34BQ36321564-89B24C04-70F3-4F17-9A41-3143D3C7A6AAQ36331126-B145D288-6CBC-4B6C-9651-E513CC4D6C32Q36458797-45827838-ECD0-4AD0-AC53-AFB26AE9A325Q36458853-664335CD-2854-48A1-831F-7807991DED71Q36594607-39A864D4-CA50-4BC9-9CCF-5C713C065FCBQ38378845-406490DC-EFF1-4FCC-B694-D22D549C7F55Q38380827-702A7EE2-EB59-44CE-87E8-75EFD2B4F9A8Q38386660-F36FC635-FC9D-4B65-BFC6-8316BDBF2DF3Q38411840-89B34503-044E-4E0D-BABE-410665C19519Q38513891-A3C96DA7-48FE-46BD-8E81-3907C78F2FE6Q38589753-E9C7A356-987B-4E3A-A908-249CDD20C39CQ38608242-87B82334-DDF5-45C9-9EEB-5F8588EB90BFQ38613869-FB5D190C-0A9C-4829-A3C2-3ADDED56341FQ38620930-A78BAAA6-F13B-4D5B-A189-B9213B5823EBQ38631033-089CAE9C-DD05-4289-AC67-0452BBFF51F4Q38704892-5A2BE73B-6916-4B85-ADB7-42B569F9A836Q38748850-F8810BF6-840D-40BE-841E-32A5796FD018Q38777127-714E2A58-F80A-4DEE-ACBC-78FADB2B2A2CQ38826010-6B2F1C67-6314-4466-9315-3F475EB0045EQ38830358-67A9F274-94FD-4410-96C2-DDD519525BCBQ38838530-4BDB1963-37C9-4F4A-AF90-C4EF343F3CBCQ38893463-1B82ECA7-F23E-4AF4-9A42-895F1021FF43Q38910667-B474A4FB-83A9-450A-AB58-ABC8A091738BQ38936364-F300BAA1-F414-44DF-8CC8-6594CF7DF23E
P2860
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@ast
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@en
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@nl
type
label
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@ast
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@en
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@nl
prefLabel
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@ast
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@en
Laboratory measurement of the ...... vitamin K oral anticoagulants.
@nl
P2860
P921
P1476
Laboratory measurement of the ...... -vitamin K oral anticoagulants
@en
P2093
Adam Cuker
David A Garcia
P2860
P304
P356
10.1016/J.JACC.2014.05.065
P407
P577
2014-09-01T00:00:00Z